DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Lung cancer presentation and diagnostic pathway

Essential points for quick revision.

Synopsis

Recognise suspected lung cancer promptly and sequence imaging, tissue, staging and fitness assessment so each test answers a treatment decision without avoidable duplication or delay.

  • Persistent or unexplained haemoptysis, cough, breathlessness, chest or shoulder pain, weight loss, hoarseness, clubbing, lymphadenopathy or recurrent focal infection can signal lung cancer.
  • Follow NICE suspected-cancer referral criteria: urgent chest imaging or pathway referral is driven by age, smoking history, symptom combinations and abnormal imaging, not by a single universal presentation.
  • A normal chest radiograph does not exclude central, small or hidden lung cancer when clinical concern persists; review the image and escalate according to the whole presentation.

Key red flags

Life-threatening haemoptysis requires airway, oxygenation, haemodynamic resuscitation and urgent interventional or surgical coordination before the routine diagnostic sequence.

Investigation priorities

01
Chest radiographFirst step

Provide rapid initial imaging for symptom-triggered suspected lung cancer.

Management branches

SUSPECTMove from symptom to urgent assessment

NICE referral criteria, concerning persistent symptoms, abnormal chest imaging or a compatible paraneoplastic syndrome.

  1. Take a focused symptom, smoking and occupational history, examine for nodes, effusion, collapse, clubbing and metastatic or emergency features, and review prior imaging.
  2. Apply current NICE NG12 criteria for urgent radiography or suspected-cancer referral, documenting why persistent concern remains if the initial chest radiograph is normal.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom